Blog Archives - SENS Research Foundation

Blog

AmyloSENS Therapies for Alzheimer’s: The Marathon and the Decathlon

The Phase III trials for AmyloSENS rejuvenation biotechnologies lecanemab/Leqembi® and donanemab showed that they are most effective when given to people with less of other kinds of cellular and molecular aging damage in their brains. New data illustrates that fact even more powerfully and gives us a foreshadowing of what’s possible if we make best use of these and forthcoming damage-repair longevity therapeutics.

February 8, 2024 No Comments

Blog

More Studies on Metformin and Survival

In this update, we review two recent papers that address the question of people with type 2 diabetes who take metformin living longer than people without the disease who don’t, but without the flaw in the 2014 study. We find that, as expected, metformin is a good diabetes drug but shows no sign of being a longevity therapeutic.

September 6, 2023 No Comments

Education

Sponsor a Student

SENS Research Foundation (SRF) is launching its campaign Sponsor a Student to increase charitable donations that will allow it to hire more student researchers and teach them that aging is not indisputable. Sponsoring a student dramatically transforms a young person’s life, giving them a chance to conduct world-class research and learn more about the career that awaits them.

August 14, 2023 No Comments

Blog

Set My Heart Free: Two AmyloSENS Therapies Targeting Cardiac Amyloid in Clinical Trials

TTR cardiac amyloid contributes to heart failure and appears to limit the lives of the longest-lived humans. One AmyloSENS antibody shows high promise to remove this amyloid and restore function in the aging heart in an early-stage clinical trial. A second such antibody is coming close behind it, and a tiny number of people’s immune systems appear to generate such antibodies on their own.

August 2, 2023 No Comments

Blog

The Grand Opening of Our New Facilities

June 23, 2023 – SRF had the Grand Opening of our expanded Research Center in Mountain View, CA. In attendance were local and state dignitaries, members of the SRF Board, SRF senior staff and scientific leads, SRF staff and Education program participants, and a number of distinguished and welcome guests.

July 9, 2023 No Comments

Blog

From Parachutes to Jetpacks: Clearing Brain Beta-Amyloid with Donanemab or Lecanemab Works, Though More Must be Done

Another clinical trial has now proven that a second AmyloSENS rejuvenation biotechnology that clears beta-amyloid aggregates from the brain also slows down the slide into dementia in people in the early stages of Alzheimer’s disease, but this development is only the beginning.

June 5, 2023 No Comments

TRIMming Tau Damage in Its Foxholes

Aberrant tau inside neurons is a key driver of Alzheimer’s disease, but nearly all the therapies in development to target it can only capture the small amount that floats outside of them. A new animal study reports impressive results in clearing aberrant tau inside neurons and rejuvenating cognitive function, opening up an important new front in damage-repair strategies for maintaining the aging brain.

Michael Rae December 5, 2024

Monkeying With the Clocks Via Metformin

A recent study claimed to find that metformin rejuvenated cognitive function in aging monkeys and lowered biological age on a nonhuman primate biological age clock. The details make the result unconvincing.

Michael Rae October 12, 2024

SENSible Question: Should We Engineer Our Mitochondria to be More Like Birds, or is That a Wild Goose Chase?

A supporter asks: Everyone knows that mitochondrial free radicals are a key driver of aging, and antioxidants don’t seem to offer any protection. Birds are supposed to have very clean-burning mitochondria, so should you maybe try to cut them off at the source by re-engineering our mitochondria to be more like those of birds?

Michael Rae September 30, 2024

SENSible Question: How Secure a Mitochondrial “Backup” is Allotopic Expression?

A supporter asks if “backing up” copies of the mitochondrially-encoded genes in the nucleus is really viable, granted free radical damage in the nucleus. We emphasize the many additional ways that the nuclear copies will be safer than the mitochondrial originals, that the “backup copies” can be backed up again, and how they and additional strategies will buy us time for even better solutions.

Michael Rae August 31, 2024

Legs of Iron, Feet of Clay

Aging muscles lose strength above and beyond what would be expected from the mere loss of muscle mass. Accordingly, many drugs have been shown to stimulate muscle growth in older people, but the increased muscle mass consistently fails to translate into increased strength and physical function. To let people live independent lives for longer, we need damage-repair longevity therapeutics to repair the cellular and molecular damage that makes aging muscle dysfunctional.

Michael Rae August 10, 2024

Get the Message: mRNA to Target Intracellular Aggregates

Several pharma companies are currently running clinical trials on damage-repair therapies targeting damaged forms of the protein tau to combat Alzheimer’s disease. But these AmyloSENS therapies only reach tau in the fluid outside of neurons, when what we need is to clear damaged tau inside of them. Fortunately, researchers are beginning to use mRNA — the same revolutionary biotechnology platform of the best COVID vaccines — to develop new LysoSENS therapies to do just that.

Michael Rae July 6, 2024

Viva Viagra? Firmer Methodologies Needed

A recent preprint reports that use of Viagra and related drugs is associated with a lower mortality rate, raising hopes that it might be repurposed as a longevity therapeutic. Unfortunately, the methodology used in this and other recent studies is too weak to arouse too much excitement just yet.

Michael Rae May 30, 2024

SENSible Question: Beta-Amyloid and Dementia: “Never” is a Very Long Time

An article criticizes the diagnosis of Alzheimer’s in its earliest stages based on the presence of beta-amyloid or other aging damage in the brain and read this post to understand why this critique may be unfounded.

Michael Rae April 26, 2024

Repairing the Damage to Shake Off Parkinson’s

How SENS “damage-repair” longevity therapeutics can prevent and reverse the second most common neurodegenerative disease: neurodegenerative aging of the Parkinson’s type.

Michael Rae April 7, 2024

SENS Research Foundation and Lifespan.io Announce Intent to Merge, Forming a Novel Longevity Entity

In a groundbreaking announcement set to impact the future of longevity research and outreach, two historic longevity nonprofits —SENS Research Foundation and Lifespan.io (Lifespan Extension Advocacy Foundation)—have unveiled plans to merge, upon completion of regulatory approvals.

SRF April 3, 2024

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Category: Blog

AmyloSENS Therapies for Alzheimer’s: The Marathon and the Decathlon

More Studies on Metformin and Survival

Sponsor a Student

Set My Heart Free: Two AmyloSENS Therapies Targeting Cardiac Amyloid in Clinical Trials

The Grand Opening of Our New Facilities

From Parachutes to Jetpacks: Clearing Brain Beta-Amyloid with Donanemab or Lecanemab Works, Though More Must be Done

TRIMming Tau Damage in Its Foxholes

Monkeying With the Clocks Via Metformin

SENSible Question: Should We Engineer Our Mitochondria to be More Like Birds, or is That a Wild Goose Chase?

SENSible Question: How Secure a Mitochondrial “Backup” is Allotopic Expression?

Legs of Iron, Feet of Clay

Get the Message: mRNA to Target Intracellular Aggregates

Viva Viagra? Firmer Methodologies Needed

SENSible Question: Beta-Amyloid and Dementia: “Never” is a Very Long Time

Repairing the Damage to Shake Off Parkinson’s

SENS Research Foundation and Lifespan.io Announce Intent to Merge, Forming a Novel Longevity Entity

About Us

Our Research

Education Opportunities

Get Involved

Receive our NewslEtter

We respect your privacy. You can unsubscribe at any time.

About Us

Our Research

Education Opportunities

Get Involved

Receive our NewslEtter

We respect your privacy. You can unsubscribe at any time.

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can